Benzodiazepines (BDZs) bind to the gamma sub-unit of the GABA-A receptor. Their binding causes an allosteric (structural) modification of the receptor that results in an increase in GABA A receptor activity. BDZs do not substitute for GABA, which bind at the alpha sub-unit, but increase the frequency of channel opening events which leads to an increase in chloride ion conductance and inhibition of the action potential.1
Related content
Continuous maintenance therapy is associated with a lower risk of relapse than intermittent treatment, supporting ongoing treatment strategies in schizophrenia and related psychotic disorders.
Treatment response tends to be higher during a first episode than during subsequent episodes, emphasizing the importance of early intervention and effective management.
Negative symptoms are a core feature of schizophrenia and can have a profound impact on functioning, social relationships, and quality of life.